CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion.

ABSTRACT:

Aims

T cells drive adverse cardiac inflammation and ischemia-reperfusion injury following myocardial infarction (MI). Here, we aimed to test the extent to which T cell inhibition protected cardiac function following MI in mice.

Methods and results

Cardiac ischemia-reperfusion injury (CIRI), mimicking MI with successful reperfusion therapy, was induced in C57BL/6J mice via temporary surgical ligation of the left anterior descending artery. T cell inhibition was achieved using abatacept, an FDA-approved CTLA-4-Ig fusion protein. Multiple treatment strategies were assessed, ranging from prolonged treatment across 4 weeks to short-term treatment, also with delayed time-to-intervention. Cardiac function was assessed using echocardiography, including strain analysis. Impacts on th

SUBMITTER: Noonan J 

PROVIDER: S-EPMC12560771 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature